Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Plus Therapeutics Inc (PSTV)

Plus Therapeutics Inc (PSTV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,182
  • Shares Outstanding, K 9,222
  • Annual Sales, $ 300 K
  • Annual Income, $ -8,240 K
  • 60-Month Beta 0.34
  • Price/Sales 62.70
  • Price/Cash Flow N/A
  • Price/Book 4.88
Trade PSTV with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -0.31
  • Number of Estimates 1
  • High Estimate -0.31
  • Low Estimate -0.31
  • Prior Year -0.28
  • Growth Rate Est. (year over year) -10.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.96 +6.12%
on 04/16/21
3.39 -38.64%
on 03/23/21
-0.67 (-24.36%)
since 03/16/21
3-Month
1.96 +6.12%
on 04/16/21
5.42 -61.62%
on 02/10/21
-0.22 (-9.57%)
since 01/15/21
52-Week
1.40 +48.57%
on 04/27/20
5.42 -61.62%
on 02/10/21
+0.53 (+34.19%)
since 04/16/20

Most Recent Stories

More News
Plus Therapeutics to Announce First Quarter 2021 Financial Results and Host Conference Call on April 22, 2021

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, announced...

PSTV : 2.08 (+0.97%)
Piramal Pharma Solutions Enters Into a Master Services Agreement with Plus Therapeutics, Inc.

, /PRNewswire/ -- Piramal Pharma Limited's (PPL) Contract Development and Manufacturing Organization (CDMO), Piramal Pharma Solutions (PPS), announced today that the Company has entered into a Master...

PSTV : 2.08 (+0.97%)
Plus Therapeutics Enters Into Master Services Agreement with Piramal Pharma Solutions, a Leading Contract Development and Manufacturing Organization

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced that it has...

PSTV : 2.08 (+0.97%)
Plus Therapeutics to Participate in Upcoming Virtual Conferences

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced that Marc Hedrick,...

PSTV : 2.08 (+0.97%)
Plus Therapeutics to Participate in Upcoming Virtual Conferences

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced that Marc Hedrick,...

PSTV : 2.08 (+0.97%)
Thinking about buying stock in Powerbridge Technologies, BioCryst Pharma, Oramed Pharma, Ampio Pharma, or Plus Therapeutics?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PBTS, BCRX, ORMP, AMPE, and PSTV.

AMPE : 1.5700 (unch)
BCRX : 11.24 (-0.88%)
PBTS : 1.9100 (-5.91%)
PSTV : 2.08 (+0.97%)
ORMP : 8.45 (-3.76%)
Plus Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights

- Positive interim data through cohort five for the ReSPECT(TM) Phase 1 clinical trial in recurrent glioblastoma, announced November 2020 -

PSTV : 2.08 (+0.97%)
Thinking about buying stock in Can Fite Biopharma, Celsion Corp, Remark Holdings, Plus Therapeutics, or SenesTech?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CANF, CLSN, MARK, PSTV, and SNES.

CANF : 2.09 (-4.13%)
PSTV : 2.08 (+0.97%)
CLSN : 1.0600 (-10.92%)
MARK : 1.8300 (-3.68%)
SNES : 1.4700 (-2.00%)
Plus Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on February 22, 2021

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, that the Company...

PSTV : 2.08 (+0.97%)
Plus Therapeutics to Participate in BIO CEO & Investor Digital Conference

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, today announced...

PSTV : 2.08 (+0.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Plus Therapeutics Inc. is a clinical-stage pharmaceutical company. It engages in developing treatments for cancer and other diseases primarily in the United States. The company's product candidate consists of DocePLUS which are in clinical stage. Plus Therapeutics Inc., formerly known as Cytori Therapeutics...

See More

Key Turning Points

3rd Resistance Point 2.27
2nd Resistance Point 2.19
1st Resistance Point 2.13
Last Price 2.08
1st Support Level 1.99
2nd Support Level 1.91
3rd Support Level 1.85

See More

52-Week High 5.42
Fibonacci 61.8% 3.88
Fibonacci 50% 3.41
Fibonacci 38.2% 2.94
Last Price 2.08
52-Week Low 1.40

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar